logo

CDTX(Delisted)

Cidara Therapeutics·NASDAQ
--
--(--)
5.47 / 10
Netural

Fundamental metrics indicate moderate status (5.5/10). Bullish considerations: Asset-MV and Revenue-MV, with caution warranted for Current assets turnover ratio and Income tax / Total profit (%). Final rating: selective.

Fundamental(5.47)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight30.49%
1M Return9.48%
Total operating revenue (YoY growth rate %)
Value78.91
Score2/3
Weight3.19%
1M Return1.21%
Days sales outstanding
Value72.45
Score2/3
Weight-0.44%
1M Return-0.18%
PB-ROE
Value0.97
Score2/3
Weight31.27%
1M Return8.82%
Basic earnings per share (YoY growth rate %)
Value68.93
Score3/3
Weight5.20%
1M Return2.04%
Rate of return on total assets (%)
Value-38.56
Score3/3
Weight4.62%
1M Return1.75%
Income tax / Total profit (%)
Value-5.85
Score0/3
Weight-3.02%
1M Return-1.27%
Current assets turnover ratio
Value1.78
Score1/3
Weight-1.18%
1M Return-0.48%
Annualized return on total assets (%)
Value-51.41
Score3/3
Weight4.62%
1M Return1.75%
Asset-MV
Value-0.45
Score2/3
Weight25.24%
1M Return7.71%
Is CDTX fundamentally strong?
  • CDTX scores 5.47/10 on fundamentals and holds a Fair valuation at present. Backed by its -45.22% ROE, 0.00% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 51.68% earnings growth, these metrics solidify its Netural investment rating.